Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma

Amanda Duplan, Conn Mallett, Yead Jewel, Miso Park, Preeti Sharma, Asaul Gonzalez, Kevin Ly, Hyeran Choi, Bea Parcutela, Carmina Ladra, Amrita Krishnan, Flavia Pichiorri, John Williams

Blood (2025) 146 (Supplement 1): 2161.

https://doi.org/10.1182/blood-2025-2161

Published: 2025

Journal Articles

Immune population dynamics predict multiple myeloma progression while on daratumumab maintenance therapy following autologous stem cell transplant

Ryan Woodall, Alexander Pozhitkov, Azra Borogovac, Theophilus Tandoh, Alexander Brummer, Vikram Adhikarla, James Sanchez, Hearn Cho, Jeffrey Matous, Jesús Berdeja, Amrita Krishnan, Russell Rockne, Flavia Pichiorri

Blood (2025) 146 (Supplement 1): 7451.

https://doi.org/10.1182/blood-2025-7451

Published: 2025

Journal Articles

Anti-CD38 targeted radiation is effective and enhances CAR-T cell recruitment and expansion in resistant extramedullary multiple myeloma

Enrico Caserta, Vikram Adhikarla, Maxim Kuznetkov, Ruby Espinosa, Mariam Murtadha, James Sanchez, Scott Goldsmith, Amrita Krishnan, Russell Rockne, John Shively, Xiuli Wang, Flavia Pichiorri

Blood (2025) 146 (Supplement 1): 801.

https://doi.org/10.1182/blood-2025-801

Published: 2025

Journal Articles

A compact, anti-CD38 T-cell engager with a short half-life demonstrates superior anti-myeloma activity over traditional bispecific antibodies

Preeti Sharma, Miso Park, Mariam Murtadha, Milad Moloudizargari, Enrico Caserta, Ottavio Napolitano, Theophilus Tandoh, James Sanchez, Guido Marcucci, John Williams, Flavia Pichiorri

Blood (2025) 146 (Supplement 1): 799.

https://doi.org/10.1182/blood-2025-799

Published: 2025

Journal Articles

BT1: A CD84-targeting T-cell engager for selective eradication of leukemic stem cells in Acute Myeloid Leukemia

Ottavio Napolitano, Miso Park, Mariam Murtadha, Enrico Caserta, Milad Moloudizargari, Preeti Sharma, James Sanchez, Guido Marcucci, John Williams, Flavia Pichiorri

Blood (2025) 146 (Supplement 1): 3286.

https://doi.org/10.1182/blood-2025-3286

Published: 2025

Journal Articles

A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ–induced CD38 expression

Blood (2024) 143 (16): 1599–1615.

https://doi.org/10.1182/blood.2023021570

Published: 2024

Includes: Supplemental data

Journal Articles

Herpesvirus Entry Mediator As a Novel Therapeutic Target in Multiple Myeloma

Blood (2023) 142 (Supplement 1): 3296.

https://doi.org/10.1182/blood-2023-190157

Published: 2023

Journal Articles

IL1RAP-Specific T Cell Engager (TCE) Antibody Efficiently Depletes Acute Myeloid Leukemia (AML) Leukemic Stem Cells (LSCs)

Blood (2023) 142 (Supplement 1): 586.

https://doi.org/10.1182/blood-2023-185405

Published: 2023

Journal Articles

CD38-Directed, Single-Chain T Cell-Engager Targets Leukemia Stem Cells through IFNγ-Induced CD38 Expression

Blood (2023) 142 (Supplement 1): 2797.

https://doi.org/10.1182/blood-2023-189901

Published: 2023

Journal Articles

Poseidon - a Collaborative Environment for the Daratumumab Sensitivity Research Trial

Alexander Pozhitkov, Theophilus Tandoh, Mahmoud Singer, Allen Mao, Flavia Pichiorri, Samir Courdy

Blood (2023) 142 (Supplement 1): 7177.

https://doi.org/10.1182/blood-2023-182239

Published: 2023

Journal Articles

CD84 Is a Therapeutically Targetable Driver of Leukemogenesis Via Disruption of Energy Supply in Acute Myeloid Leukemia

Yinghui Zhu, Miso Park, Mariam Murtadha, Enrico Caserta, Le Xuan Truong Nguyen, Mahmoud Singer, Marc Denisse Estepa, Lokesh Nigam, Ada Alice Dona', James F Sanchez, Theophilus Tandoh, Man Li, Bin Zhang, Ya-Huei Kuo, Guido Marcucci, John C Williams, Flavia Pichiorri

Blood (2022) 140 (Supplement 1): 89–90.

https://doi.org/10.1182/blood-2022-170300

Published: 2022

Journal Articles

Sumoylation Inhibition Potentiates Daratumumab Activity Against Multiple Myeloma

Li Du, Wei Liu, Enrico Caserta, Flavia Pichiorri, Steve T Rosen

Blood (2022) 140 (Supplement 1): 9972–9973.

https://doi.org/10.1182/blood-2022-158040

Published: 2022

Journal Articles

OM301, a Synthetic Polypeptide Containing the p53TA (Transactivation) Domain, Impairs Mitochondrial Activity and Survival of Myeloma Cells

Lokesh Nigam, Yinghui Zhu, Estelle Troadec, Enrico Caserta, Ada Dona', James F Sanchez, Amrita Y. Krishnan, Le Xuan Truong Nguyen, Guido Marcucci, Flavia Pichiorri

Blood (2021) 138 (Supplement 1): 2661.

https://doi.org/10.1182/blood-2021-151506

Published: 2021

Journal Articles

FLT3-ITD Activates Cytoplasmic Drosha-Dependent Non-Canonical Mechanisms of Mir-155 Biogenesis in Acute Myeloid Leukemia

Le Xuan Truong Nguyen, PhD, Bin Zhang, PhD, Dinh Hoa Hoang, BS, Dandan Zhao, MD, Sergio Branciamore, Davide Maestrini, PhD, Yu-Lin SU, PhD, Sonia Rodriguez, PhD, Flavia Pichiorri, PhD, Steven Rosen, MD, Michael A. Caligiuri, MD, Stephen J. Forman, MD, Ling Li, PhD, Marcin Kortylewski, PhD, Russell Rockne, PhD, Ya-Huei Kuo, PhD, Nadia Carlesso, MD, Guido Marcucci, MD

Blood (2019) 134 (Supplement_1): 2722.

https://doi.org/10.1182/blood-2019-131871

Published: 2019

Journal Articles

Targeting MiR-126 Blocks Progression of Myelodysplastic Syndrome and Transformation into Acute Myeloid Leukemia

Huafeng Wang, MD, Jie Sun, PhD, Dandan Zhao, MD, Hongyan Tong, Herman Wu, BS, Xia Li, PhD, Yingwan Luo, MD, Dan Dong, PhD, Tinisha McDonald, MS, Anthony Stein, MD, Monzr M. Al Malki, MD, Flavia Pichiorri, PhD, Nadia Carlesso, MD, Ya-Huei Kuo, PhD, Bin Zhang, PhD, Guido Marcucci, MD, Ling Li, PhD, Jie Jin, MD PhD

Blood (2019) 134 (Supplement_1): 1707.

https://doi.org/10.1182/blood-2019-130375

Published: 2019

Journal Articles

Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

Ada Dona', PhD, Domenico Viola, Enrico Caserta, PhD, Francesca Besi, PhD, James F Sanchez, PhD, Guido Marcucci, MD, Jonathan J Keats, PhD, Amrita Y. Krishnan, MD, Matt Coffey, PhD, Douglas W. Sborov, MDMSc, Gerard Nuovo, MD, Craig C Hofmeister, MDMPH, Flavia Pichiorri, PhD

Blood (2019) 134 (Supplement_1): 1816.

https://doi.org/10.1182/blood-2019-128740

Published: 2019

Journal Articles

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Blood (2019) 134 (Supplement_1): 4394.

https://doi.org/10.1182/blood-2019-126080

Published: 2019

Journal Articles

Downregulation of Mir-142 Promotes Leukemia Growth in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): A Possible Novel Therapeutic Target?

Blood (2018) 132 (Supplement 1): 1338.

https://doi.org/10.1182/blood-2018-99-119599

Published: 2018

Journal Articles

Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses

Craig C Hofmeister, MDMPH, Douglas W. Sborov, MD MS, Domenico Viola, Ada Dona, Gerald J Nuovo, PhD, Don M. Benson, Jr., MD PhD, Sagar Lonial, MD, Jonathan L Kaufman, MD, Ajay K Nooka, MD MPH, Leonard Heffner, MD, Madhav V Dhodapkar, MD, Flavia Pichiorri, PhD

Blood (2018) 132 (Supplement 1): 2655.

https://doi.org/10.1182/blood-2018-99-113500

Published: 2018

Journal Articles

Immune Mediated Mechanisms of Resistance to Daratumumab

Domenico Viola, Ada Dona, Emine Gulsen Gunes, PhD, Estelle Troadec, Xiwei Wu, Sergio Branciamore, Tinisha McDonald, MS, Lucy Ghoda, PhD, Ashish Streatfield, James F Sanchez, PhD, Chatchada Karanes, Myo Htut, Michael Rosenzweig, Jonathan J Keats, PhD, Steven T Rosen, Guido Marcucci, Amrita Krishnan, MD, Flavia Pichiorri, PhD

Blood (2018) 132 (Supplement 1): 3201.

https://doi.org/10.1182/blood-2018-99-117441

Published: 2018

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Leveraging novel CD38 targeted antibody-drug-conjugates for the treatment of multiple myeloma

Immune population dynamics predict multiple myeloma progression while on daratumumab maintenance therapy following autologous stem cell transplant

Anti-CD38 targeted radiation is effective and enhances CAR-T cell recruitment and expansion in resistant extramedullary multiple myeloma

A compact, anti-CD38 T-cell engager with a short half-life demonstrates superior anti-myeloma activity over traditional bispecific antibodies

BT1: A CD84-targeting T-cell engager for selective eradication of leukemic stem cells in Acute Myeloid Leukemia

A CD38-directed, single-chain T-cell engager targets leukemia stem cells through IFN-γ–induced CD38 expression

Herpesvirus Entry Mediator As a Novel Therapeutic Target in Multiple Myeloma

IL1RAP-Specific T Cell Engager (TCE) Antibody Efficiently Depletes Acute Myeloid Leukemia (AML) Leukemic Stem Cells (LSCs)

CD38-Directed, Single-Chain T Cell-Engager Targets Leukemia Stem Cells through IFNγ-Induced CD38 Expression

Poseidon - a Collaborative Environment for the Daratumumab Sensitivity Research Trial

CD84 Is a Therapeutically Targetable Driver of Leukemogenesis Via Disruption of Energy Supply in Acute Myeloid Leukemia

Sumoylation Inhibition Potentiates Daratumumab Activity Against Multiple Myeloma

OM301, a Synthetic Polypeptide Containing the p53TA (Transactivation) Domain, Impairs Mitochondrial Activity and Survival of Myeloma Cells

FLT3-ITD Activates Cytoplasmic Drosha-Dependent Non-Canonical Mechanisms of Mir-155 Biogenesis in Acute Myeloid Leukemia

Targeting MiR-126 Blocks Progression of Myelodysplastic Syndrome and Transformation into Acute Myeloid Leukemia

Proteasome Inhibitors Impair the Innate Antiviral Immune Response and Potentiate Pelareorep-Based Viral Therapy in Multiple Myeloma

First-in-Human Imaging of Multiple Myeloma Using Copper-64-Labeled Daratumumab: Preliminary Results

Downregulation of Mir-142 Promotes Leukemia Growth in Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL): A Possible Novel Therapeutic Target?

Oncolytics Virus Replication Using Pelareorep (Reolysin) and Carfilzomib in Relapsed Myeloma Patients Increases PD-L1 Expression with Clinical Responses

Immune Mediated Mechanisms of Resistance to Daratumumab

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only